Neoprobe Corporation (AMEX: NEOP)
3/29/2011, we released our published research report, "TooNiceStocks Initiates Coverage on Neoprobe Corporation (AMEX: NEOP) - Researching the Near Term Catalyst, Fundamental and Product Pipeline". Our members were notified @ $2.48 and ran to $4.25 rallying up to 71.37%. In February, NEOP had a meeting with the U.S. Food and Drug Administration re-initiated the development for the RIGScan CR technology for detection of colorectal cancer tumors. Please read our original report here.


